A recent systematic review found that opioid misuse in cancer patients is highly prevalent, with rates ranging from 5.7% to 84.0%. The prevalence of opioid misuse risk varied between 2.4% and 35.4%, with a pooled prevalence of 12.3%.
The observed disparities in opioid misuse percentages underscore the need for more studies using standardized definitions, validated assessment tools and consistent research methods to accurately address this issue in patients with cancer, according to the review